Adia Nutrition, Inc. Annual Report: A Plain-English Guide

I’ve put together this guide to help you understand Adia Nutrition’s performance over the past year. My goal is to break down their financial filings so you can decide if this company belongs in your portfolio.

1. The Big Picture

Adia Nutrition has moved past its "shell company" phase and is now an active business in regenerative medicine. They operate through two divisions: Adia Med (clinics) and Adia Labs (stem cell and exosome products). The company focuses on selling human cellular and tissue-based products to the orthopedic and aesthetic markets, betting that these therapies will become mainstream for treating pain and aging.

2. Financial Health: The Reality Check

The latest numbers show the company is in a difficult position.

• Growing Losses: In 2025, the company lost $395,464, more than double its $181,067 loss in 2024. With only $112,500 in revenue for 2025, the gap between costs and incoming cash is widening.
• The "Going Concern" Warning: Auditors have issued a "substantial risk" warning, noting that the company may not survive because it spends cash faster than it earns it. As of December 31, 2025, the company held only $42,120 in cash—not enough to cover its planned expenses for the coming year.
• Accumulated Debt: The company has an accumulated deficit of nearly $16 million, largely from past restructuring and early research costs.

3. Operational Wins and Risks

• Strategic Progress: They secured AATB accreditation for their labs, a vital step for distributing human tissue products. They are also using a "hub and spoke" model: they run flagship clinics while selling products to other facilities. This helps them scale without the high cost of opening many physical locations.
• Operational Constraints: This is a tiny operation with only three full-time employees. The CEO and CFO manage almost everything, creating "key person risk"—if a core leader leaves, the company could struggle to function.

4. What Could Go Wrong

• Regulatory Risks: Their business relies on specific FDA classifications. If the FDA reclassifies their products as "drugs," Adia would face a multi-year, multi-million dollar approval process that they likely lack the cash to survive.
• Supply Chain: They rely on one third-party lab for manufacturing. If that lab faces production issues or storage failures, Adia has no inventory to sell, which would stop their revenue entirely.
• Competition: They face 30–50 competitors, many with more cash and better distribution. If a rival launches a cheaper or better product, Adia lacks the marketing budget to compete.
• Dilution: Because they are low on cash, they will likely issue more shares. This will reduce your ownership percentage and the value of your investment.

5. The Bottom Line

Adia is in a high-risk, "growth-at-all-costs" phase. While they are targeting the regenerative medicine market, their rising losses, minimal cash, and auditor warnings are serious concerns. Treat this as a speculative venture. The risk of total loss remains high until the company proves it can turn a profit or secures a major partner to fund its operations.

Investor Tip: Before investing, ask yourself if you are comfortable with the high probability of share dilution and the company's current inability to cover its own operating costs. This is a "wait and see" situation for most conservative portfolios.